Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab in ...

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterised by scarring of lung tissue, leading ...

Nucala's approval offers hope for uncontrolled COPD. This new drug reduces flare-ups, a key benefit for Black Americans.

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in ...

Mepolizumab, a humanized monoclonal antibody that targets interleukin-5 (IL-5), significantly reduced COPD exacerbations in ...

A relatively new therapy used to treat pulmonary arterial hypertension in those with mild to moderate disease was found to be ...

Experimental Cancer Drug Could Streamline Standard Tuberculosis Treatment and Prevent Post-TB Lung Disease, Study Suggests Apr. 21, 2025 — An experimental drug now in clinical trials as a cancer ...